MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Total Equity · Q3 FY2026 · quarter ended Sep 2026
Total equity rises 22.0% from a year ago
Total equity stood at $472.95M at the end of Q3 FY2026, up 22.0% from a year earlier and up 15.5% from the prior quarter.
Context
- Total equity amounted to 94.5% of total assets at the end of Q3 FY2026, down 2.4 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +22.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 369.22M USD
- Year-over-year change
- +43.4%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 369.22M | +43.4% |
| FY2024 | 2024-12-31 | 257.44M | +455.2% |
| FY2023 | 2023-12-31 | (72.47M) | -70.1% |
| FY2022 | 2022-12-31 | (42.61M) | — |
Total Equity vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +22.0% is the 5th highest of 8, against a peer median of +70.3%.
- Total equity amounts to 94.5% of total assets for MBX, versus a peer median of 70.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €1.5B EUR | +962.0% | — | 61.8% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $1.12B USD | — | — | 92.3% |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $472.95M USD | +22.0% | — | 94.5% |
| Jun 2026 | $408.32M USD | -48.7% | +63.8% | 78.2% | |
| Mar 2026 | $283.99M USD | +99.8% | +6.7% | 84.6% | |
| Mar 2026 | $238.28M USD | +70.3% | +9.7% | 88.6% | |
| Sep 2026 | $201.54M USD | -31.8% | +0.7% | 45.5% | |
| Mar 2026 | $18.72M USD | -34.9% | -35.2% | 40.4% | |
| Mar 2026 | $13.01M USD | +137.0% | -32.8% | 3.3% | |
| Peer median (excluding MBX) | — | +70.3% | +3.7% | 70.0% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.